Impax Asset Management Group plc Acquires 600,000 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

Impax Asset Management Group plc boosted its holdings in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 52.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,754,475 shares of the company's stock after buying an additional 600,000 shares during the period. Impax Asset Management Group plc owned approximately 3.05% of Health Catalyst worth $16,246,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Advisor Group Holdings Inc. boosted its holdings in Health Catalyst by 86.3% during the first quarter. Advisor Group Holdings Inc. now owns 5,324 shares of the company's stock worth $137,000 after buying an additional 2,467 shares during the last quarter. Fairfield Bush & CO. acquired a new stake in shares of Health Catalyst in the 1st quarter valued at approximately $25,000. Raymond James Financial Services Advisors Inc. boosted its stake in Health Catalyst by 118.6% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 11,157 shares of the company's stock worth $292,000 after acquiring an additional 6,053 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Health Catalyst by 4.9% during the first quarter. Bank of New York Mellon Corp now owns 750,396 shares of the company's stock valued at $19,607,000 after purchasing an additional 35,022 shares during the period. Finally, US Bancorp DE grew its holdings in Health Catalyst by 14.0% during the first quarter. US Bancorp DE now owns 9,260 shares of the company's stock valued at $242,000 after purchasing an additional 1,139 shares during the period. 85.00% of the stock is owned by institutional investors.

Insider Transactions at Health Catalyst

In related news, insider Linda Llewelyn sold 3,163 shares of the stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $10.83, for a total transaction of $34,255.29. Following the completion of the transaction, the insider now owns 68,048 shares in the company, valued at $736,959.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research firms have weighed in on HCAT. KeyCorp reiterated a "sector weight" rating on shares of Health Catalyst in a report on Wednesday. Evercore ISI dropped their price objective on Health Catalyst from $11.00 to $10.00 and set an "outperform" rating on the stock in a research note on Friday, February 23rd. Cantor Fitzgerald reiterated an "overweight" rating and set a $16.00 target price on shares of Health Catalyst in a report on Wednesday. Guggenheim upgraded Health Catalyst from a "neutral" rating to a "buy" rating and set a $14.00 price target for the company in a report on Friday, January 26th. Finally, Canaccord Genuity Group dropped their price target on Health Catalyst from $12.00 to $11.00 and set a "buy" rating on the stock in a research report on Friday, February 23rd. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $12.18.

Health Catalyst Stock Down 6.7 %

Shares of Health Catalyst stock traded down $0.45 during trading on Wednesday, reaching $6.23. The stock had a trading volume of 1,065,966 shares, compared to its average volume of 617,526. The company has a current ratio of 4.42, a quick ratio of 4.42 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $364.83 million, a price-to-earnings ratio of -2.97 and a beta of 1.29. Health Catalyst, Inc. has a 52 week low of $6.06 and a 52 week high of $14.37. The stock has a fifty day moving average price of $8.43 and a two-hundred day moving average price of $8.61.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last released its earnings results on Thursday, February 22nd. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.06. Health Catalyst had a negative return on equity of 12.19% and a negative net margin of 39.92%. The firm had revenue of $75.08 million for the quarter, compared to analysts' expectations of $73.67 million. Sell-side analysts predict that Health Catalyst, Inc. will post -0.47 EPS for the current fiscal year.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.